Sarah C Patterson

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Advanced Cancer

Diffuse Large B Cell Lymphoma

Gold Nanoparticles

Top Venues

Molecular cancer therapeutics

bioRxiv : the preprint server for biology

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism. Molecular cancer therapeutics 23 (7) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism. Molecular cancer therapeutics 23 (7) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Haeun Hwangbo, Sarah C Patterson, Andy Dai, Deborah Plana, Adam C Palmer
Additivity predicts the efficacy of most approved combination therapies for advanced cancer. Nature cancer (2023)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. bioRxiv : the preprint server for biology (2023)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. bioRxiv : the preprint server for biology (2023)